One Fewer Event for Every Seventy Patients
A large analysis of United States insurance claims has linked tirzepatide to a lower rate of heart attacks and deaths among people with type 2 diabetes who already have heart disease, and the size of that effect is worth understanding precisely rather than in headline terms.
